These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 35371346)
1. 5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer. Li Z; Wang S; Chen Y; Huang Y; Li T Dis Markers; 2022; 2022():3117359. PubMed ID: 35371346 [TBL] [Abstract][Full Text] [Related]
2. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Lu H; Wu J; Liang L; Wang X; Cai H Front Immunol; 2022; 13():803355. PubMed ID: 35154117 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K Front Immunol; 2021; 12():800268. PubMed ID: 34956238 [TBL] [Abstract][Full Text] [Related]
4. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H Front Immunol; 2022; 13():916800. PubMed ID: 35860239 [TBL] [Abstract][Full Text] [Related]
5. RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update. He RQ; Huang ZG; Li TY; Wei YP; Chen G; Lin XG; Wang QY Cell Physiol Biochem; 2018; 50(4):1474-1495. PubMed ID: 30359990 [TBL] [Abstract][Full Text] [Related]
6. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
7. The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma. He C; Zhu X; Kong F; Zhang X; Chai X; Zou C; Zhao D Biomed Res Int; 2022; 2022():2747799. PubMed ID: 35711526 [TBL] [Abstract][Full Text] [Related]
8. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer. Tan Z; Fu S; Zuo J; Wang J; Wang H Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832 [TBL] [Abstract][Full Text] [Related]
9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
10. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer. Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694 [TBL] [Abstract][Full Text] [Related]
11. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881 [TBL] [Abstract][Full Text] [Related]
12. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer. Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763 [TBL] [Abstract][Full Text] [Related]
13. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer. Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer. Li H; Zhang Y; Zheng S Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692 [TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs. Yang X; Zhang Y; Liu J; Feng Y Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515 [TBL] [Abstract][Full Text] [Related]
16. ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment. Pan W; Liu X; Liu S Medicine (Baltimore); 2024 Apr; 103(14):e37590. PubMed ID: 38579085 [TBL] [Abstract][Full Text] [Related]
17. Development of the expression and prognostic significance of m Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884 [TBL] [Abstract][Full Text] [Related]
18. Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma. Zhang C; Li Z; Hu J; Qi F; Li X; Luo J J Cell Biochem; 2020 Jan; 121(1):856-866. PubMed ID: 31373406 [TBL] [Abstract][Full Text] [Related]
19. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma. Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y Front Immunol; 2021; 12():806189. PubMed ID: 35095893 [TBL] [Abstract][Full Text] [Related]
20. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Hu Y; Chen Y Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]